1-Phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for Taxol and vincristine

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 942-948

  Sietsma, Hannie ^a,c   Veldman, Robert Jan ^c   Kolk, Dorina V D ^b   Ausema, Bertien ^c   Nijhof, Willem ^c   Kamps, Willem ^a   Vellenga, Edo ^b   Kok, Jan Willem ^b,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; CERAMIDE; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; VALSPODAR; VERLUKAST; VINCRISTINE;

ANIMAL CELL; ARTICLE; CELL METABOLISM; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CERAMIDES; CYCLOSPORINS; DRUG SYNERGISM; ENZYME INHIBITORS; ETOPOSIDE; GLUCOSYLTRANSFERASES; MORPHOLINES; NEUROBLASTOMA; PACLITAXEL; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0034016790     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Crist, W. M., and Kun, L. E. Common solid tumors of childhood. N. Engl. J. Med., 324: 461-471, 1991.
2. Niethammer, D., and Handgretinger, R. Clinical strategies for the treatment of neuroblastoma. Eur. J. Cancer, 31A: 568-571, 1995.
3. Kuttesch, J. F. Multidrug resistance in pediatric oncology. Invest. New Drugs, 14: 55-67, 1996.
4. Norris, M. D., Bordow, S. B., Marshall, G. M., Haber, P. S., Cohn, S. L., and Haber, M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N. Engl. J. Med., 334: 231-238, 1996.
5. Lasorella, A., Iavarone, A., and Israel, M. A. Differentiation of neuroblastoma enhances bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res., 55: 4711-4716, 1995.
6. Keshelava, N., Seeger, R. C., and Reynolds, C. P. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur. J. Cancer, 33: 2002-2006, 1997.
7. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 49: 5870-5878, 1989.
8. Huschtscha, L. I., Bartier, W. A., Ross, C. E., and Tattersall, M. H. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br. J. Cancer, 73: 54-60, 1996.
9. Strum, J. C., Small, G. W., Pauig, S. B., and Daniel, L. W. 1-β-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J. Biol. Chem., 269: 15493-15497, 1994.
10. Bose, R., Verheij, M., Haimovitz Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell, 82: 405-414, 1995.
11. Jaffrezou, J. P., Levade, T., Bettaieb, A., Andrieu, N., Bezombes, C., Maestre, N., Vermeersch, S., Rousse, A., and Laurent, G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J., 15: 2417-2424, 1996.
12. Lavie, Y., Cao, H., Bursten, S. L., Giuliano, A. E., and Cabot, M. C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem., 271: 19530-19536, 1996.
13. Lavie, Y., Cao, H. T., Volner, A , Lucci, A., Han, T. Y., Geffen, V., Giuliano, A. E., and Cabot, M. C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem., 272: 1682-1687, 1997.
14. Radin, N. S., Shayman, J. A., and Inokuchi, J. Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. Adv. Lipid Res., 26: 183-213, 1993.
15. Rosenwald, A. G., Machamer, C. E., and Pagano, R. E. Effects of a sphingolipid synthesis inhibitor on membrane transport through the secretory pathway. Biochemistry, 31: 3581-3590, 1992.
16. Rosenwald, A. G., and Pagano, R. E. Inhibition of glycoprotein traffic through the secretory pathway by ceramide. J. Biol. Chem., 268: 4577-4579, 1993.
17. Kok, J. W., Babia, T., Filipeanu, C. M., Nelemans, A., Egea, G., and Hoekstra, D. PDMP blocks Brefeldin A-induced retrograde membrane transport from Golgi to ER: Evidence for involvement of calcium homeostasis and dissociation from sphingolipid metabolism. J. Cell Biology, 142: 1-14, 1998.
18. Ladisch, S. Tumor cell gangliosides. Adv. Pediatr., 34: 45-58, 1987.
19. Sietsma, H., Nijhof, W., Dontje, B., Vellenga, E., Kamps, W. A., and Kok, J. W. Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. Cancer Res., 58: 4840-4844, 1998.
20. Sietsma, H., Kamps, W. A., Dontje, B., Hendriks, D., Kok, J. W., Vellenga, E., and Nijhof, W. Leukemia-induced bone marrow depression; effects of gangliosides on erythroid cell production. Int. J. Cancer, 82: 92-97, 1999.
21. Kolk, D. M., de Vries, E. G. E., Koning, J. A., van den Berg, E., Muller, M., and Vellenga, E. Activity and expression of the multidrug resistance protein MRP1 and MRP2 in acute myeloid leukemia (AML) cells, tumor cell lines and normal hemopoietic CD34+ peripheral blood cells. Clin. Cancer Res., 4: 1727-1736, 1998.
22. Zijlstra, J. G., de Jong, S., de Vries, E. G., and Mulder, N. H. Topoisomerases, new targets in cancer chemotherapy. Med. Oncol. Tumor Pharmacother., 7: 11-18, 1990.
23. rev cells. Biochem. J., 331: 563-569, 1998.
24. Hannun, Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood, 89: 1845-1853, 1997.
25. Mathias, S., Peña, L. A., and Kolesnick, R. N. Signal transduction of stress via ceramide. Biochem. J., 335: 465-480, 1998.
26. Babia, T., Veldman, R. J., Hoekstra, D., and Kok, J. W. Modulation of carcinoembryonic antigen release by glucosylceramide. Implications for HT29 cell differentiation. Eur. J. Biochem., 258: 233-242, 1998.
27. Myrick, D., Blackinton, D., Klostergaard, J., Kouttab, N., Maizel, A., Wanebo, H., and Mehta, S. Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leuk. Res., 23: 569-578, 1999.
28. Saito, M. Bioactive gangliosides: Differentiation inducers for hematopoietic cells and their mechanism(s)of actions. Adv. in Lipid Res., 25: 303-327, 1993.
29. Merzak, A., Koochekpour, S., Mccrea, S., Roxanis, Y., and Pilkington, G. J. Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells in vitro. Mol. Chem. Neuropathol., 24: 121-135, 1995.
30. Ladisch, S., Kitada, S., and Hays, E. F. Gangliosides shed by tumor cells enhance tumor formation in mice. J. Clin. Invest., 79: 1879-1882, 1987.
31. Holleran, W. M., DeGregorio, M. W., Ganapathi, R., Wilbur, J. R., and Macher, B. A. Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells. Cancer Chemother. Pharmacol., 17: 11-15, 1986.